FDA rejects schizophrenia drug from Teva

The US health authority has given its thumbs-down for a schizophrenia drug candidate developed by Teva in a collaboration with French biotech firm Medincell.
Danish national Kåre Schultz is chief executive of Teva, which has just received the FDA's thumbs-down for its candidate drug against schizophrenia | Photo: Amir Cohen/Reuters/Ritzau Scanpix
Danish national Kåre Schultz is chief executive of Teva, which has just received the FDA's thumbs-down for its candidate drug against schizophrenia | Photo: Amir Cohen/Reuters/Ritzau Scanpix
by albert rønning-andersson, translated by daniel pedersen

A potentially new treatment for schizophrenia has been sent back to the development phase, the pharmaceutical firm behind the drug, Teva, has announced in a press release on Tuesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading